原发性及继发性血色病对心脏结构及功能影响的对比研究

肝脏 ›› 2021, Vol. 26 ›› Issue (5): 542-546.

原发性及继发性血色病对心脏结构及功能影响的对比研究

王婉溦, 武亭, 王昱, 李柯鑫, 刘立伟, 欧晓娟, 贾继东, 赵新颜

100007 北京市第六医院(王婉溦);
首都医科大学附属北京友谊医院肝病中心,国家消化系统疾病临床医学研究中心(武亭,王昱,李柯鑫,刘立伟,欧晓娟,贾继东,赵新颜)

收稿日期:2021-01-28 出版日期:2021-05-31 发布日期:2021-06-17
通讯作者: 赵新颜, Email: zhao_xinyan@ccmu.edu.cn
基金资助:
北京市医院管理局消化内科学科协同发展中心专项经费资助(XXZ0301)

Involvement of cardiac structure and function between primary and secondary hemochromatosis: a comparative study

WANG Wan-wei¹, WU Ting², WANG Yu², LI Ke-xin², LIU Li-wei², OU Xiao-juan², JIA Ji-dong², ZHAO Xin-yan²

1. Beijing No.6 Hospital;
2. Liver Research Center, Beijing Friendship Hospital, Capital Medical University; National Clinical Research Center for Digestive Disease, Beijing 100050, China

Received:2021-01-28 Online:2021-05-31 Published:2021-06-17
Contact: ZHAO Xin-yan, Email: Zhao_xinyan@ccmu.edu.cn

摘要/Abstract

摘要： 目的比较原发性血色病与继发性血色病对心脏结构及功能的影响。方法回顾分析2008年1月至2018年12月在首都医科大学附属北京友谊医院诊断为铁过载的住院患者,收集患者临床表现及实验室指标、心电图及超声心动图心脏结构参数并进行对比分析。结果原发性血色病20例,平均年龄45岁,男性14例;继发性血色病20例,平均年龄47岁,男性15例。与继发性血色病患者比较,原发性血色病患者铁蛋白显著性升高(P<0.05),肝外表现更为常见。继发性血色病和原发性血色病患者中合并心律失常分别为1例和4例,差异无统计学意义(χ²=2.057,P=0.342);两者在心电图及心脏结构主要参数方面差异无统计学意义(P>0.05)。原发性血色病2例心律失常患者中,1例房颤,1例频发室早,2例死于心力衰竭。结论原发性血色病患者铁过载程度高于继发性血色病患者,且心脏受累更为多见,包括心律失常,心力衰竭等,心脏受累往往提示预后不良。

关键词: 原发性血色病, 继发性血色病, 心律失常, 心功能衰竭

Abstract: Objective To compare the characteristics of cardiac involvement between primary and secondary hemochromatosis.Methods Patients with hemochromatosis from January 2008 to December 2018 in Beijing Friendship Hospital were retrospectively analyzed. The clinical manifestation, laboratory parameters, electrocardiogram and echocardiographic structural parameters of the patients were collected and compared. Results There were 20 cases of primary hemochromatosis (mean age 45.0 years, male 70.0%) and 20 cases of secondary hemochromatosis (mean age 47 years, male 75%). Patients with primary hemochromatosis had a significant higher level of ferritin (P<0.05) and more frequent extrahepatic manifestations than patients with secondary hemochromatosis. Cardiac arrhythmias were more common in patients with primary haemochromatosis than in patients with secondary hemochromatosis, but the difference was not statistically significant (20% vs.5%, χ² = 2.057, P=0.342). There were no significant differences in ECG and cardiac structure between two groups (P>0.05). Primary hemochromatosis included 2 patients with arrhythmias, one patient with atrial fibrillation, another one with frequent ventricular premature beats and 2 patients died of cardiac failure.Conclusion The degree of iron overload in primary hemochromatosis was significantly higher than that of secondary hemochromatosis. Cardiac involvement is more common in patients with primary hemochromatosis, including arrhythmias and heart failure. Heart involvement of hemochromatosis often indicates a poor prognosis and warrants attention of hepatologists.

Key words: Primary hemochromatosis, Secondary hemochromatosis, Arrhythmias, Heart failure

王婉溦, 武亭, 王昱, 李柯鑫, 刘立伟, 欧晓娟, 贾继东, 赵新颜. 原发性及继发性血色病对心脏结构及功能影响的对比研究[J]. 肝脏, 2021, 26(5): 542-546.

WANG Wan-wei, WU Ting, WANG Yu, LI Ke-xin, LIU Li-wei, OU Xiao-juan, JIA Ji-dong, ZHAO Xin-yan. Involvement of cardiac structure and function between primary and secondary hemochromatosis: a comparative study[J]. Chinese Hepatolgy, 2021, 26(5): 542-546.

参考文献

[1] Horns H. Hemochromatosis; cardiac failure associated with extensive hemosiderosis of the myocardium. Am J Med, 1949, 6: 272-274.
[2] Kowdley K, Brown K, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol, 2019, 114: 1202-1218.
[3] Adams P. Epidemiology and diagnostic testing for hemochromatosis and iron overload. Int J Hematol, 2015, 37: 25-30.
[4] 冯燕, 程思根, 罗志刚. 原发性血色病在中国的研究进展. 医学综述, 2014, 20: 1190-1193.
[5] Bottomley S. Secondary iron overload disorders. Semin Hematol, 1998, 35: 77-86.
[6] 赵新颜, 何志颖, 刘立伟, 等. 45例原发性与继发性血色病临床病理特点对比研究. 传染病信息, 2019, 32: 127-131.
[7] Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011, 54: 328-343.
[8] Gulati V, Harikrishnan P, Palaniswamy C, et al. Cardiac involvement in hemochromatosis. Cardiol Rev, 2014, 22: 56-68.
[9] Lin A, Yan W, Xu H, et al. Analysis of the HFE gene (C282Y, H63D and S65C) mutations in a general Chinese Han population. Tissue Antigens, 2007, 70: 252-255.
[10] Díez-López C, Comín-Colet J, González-Costello J. Iron overload cardiomyopathy: from diagnosis to management. Curr Opin Cardiol, 2018, 33: 334-340.
[11] Demant A, Schmiedel A, Büttner R, et al. Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis with iron overload cardiomyopathy. Clin Res Cardiol, 2007, 96: 900-903.
[12] Gordan R, Fefelova N, Gwathmey J K, et al. Iron overload, oxidative stress and calcium mishandling in cardiomyocytes: role of the mitochondrial permeability transition pore. Antioxidants (Basel), 2020, 9: 758.
[13] Goyal A, Mohan B, Saggar K, et al. Primary haemochromatosis resulting in dilated cardiomyopathy arising out of mutation in HJV gene in Indian patients: a rare scenario. BMJ Case Rep, 2020, 13: e235650.
[14] Barriales Alvarez V, Simarro García C, Suárez Suárez E, et al. Restrictive cardiac involvement in a patient with dyserythropoietic anemia and secondary hemochromatosis. Rev Esp Cardiol, 1996, 49: 618-620.
[15] Carpenter J, Grasso A, Porter J, et al. On myocardial siderosis and left ventricular dysfunction in hemochromatosis. J Cardiovasc Magn Reson, 2013, 15: 24.
[16] Kawabata H. The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis. Int J Hematol, 2018, 107: 31-43.
[17] Ginwalla M, Almasoud A, Tofovic D, et al. Cardiovascular evaluation and management of iron overload cardiomyopathy in sickle cell disease. Int J Lab Hematol, 2018, 93: E7-E9.
[18] Taher A, Weatherall D, Cappellini M. Thalassaemia. Lancet, 2018, 391: 155-167.
[19] Aldouri M, Wonke B, Hoffbrand A, et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol, 1990, 84: 113-117.
[20] Buja L, Roberts W. Iron in the heart. Etiology and clinical significance. Am J Med, 1971, 51: 209-221.
[21] Shizukuda Y, Bolan C, Tripodi D, et al. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. Am J Cardiol, 2006, 98: 954-959.